Survey of thorotrast-associated liver cancers in Japan.
Survey of thorotrast-associated liver cancers in Japan.
复制标题
日本胸腔镜相关肝癌的调查。
DOI：
10.1093/jnci/70.1.31
复制
发表时间：
1983
期刊：
影响因子：
--
通讯作者：
S. Takahashi
中科院分区：
文献类型：
--
作者：
S. Yamada;S. Hosoda;H. Tateno;C. Kido;S. Takahashi
93例胸腔造影剂相关肝癌尸检病例（A组）资料来源于1958 - 1979年日本病理尸检病例年鉴，78例胸腔造影剂相关肝癌尸检病例（B组）资料来源于1953 - 1980年日本文献。胆管癌（CLC）占A组的58%，占b组的55%。A组CLC患者累积数与年的曲线几乎是线性的，显示每个存活患者的风险随着时间的推移而增加。血管肉瘤（Angiosarcoma， AGS）发生率A组为25%，b组为24%。1969年后，两组发生AGS的人数均显著增加（P < 0.05）。B组AGS患者注射胸腔造影剂后年龄和年数均高于CLC患者（年龄：P < 0.05；注射胸腔造影剂后年数：P < 0.0001）。肝细胞癌（HPC）分别占A组和B组的17%和21%。当HPC患者的年分布、年龄和注射胸腔对比剂后的时间与其他肝癌患者相关时，HPC患者与CLC患者之间唯一有统计学意义的差异（P < 0.02）是在注射胸腔对比剂后的年份。自1977年以来，两组患者均出现了包括AGS在内的多发性原发性肝癌。
Data on 93 autopsy cases (group A) of thorotrast-associated liver cancers were obtained from the "Annual of Pathological Autopsy Cases in Japan" from 1958 to 1979, and data on 78 autopsy cases (group B) of thorotrast-associated liver cancers were obtained from the Japanese literature from 1953 to 1980. Cholangiocarcinoma (CLC) constituted 58% of group A and 55% of group B. The curve of the cumulative numbers of patients with CLC versus year in group A was almost linear, showing an increasing risk per surviving patients with advancing time. Angiosarcoma (AGS) occurred in 25% of group A and 24% of group B. The number of patients with AGS increased significantly after 1969 in both groups (P less than 0.05). In group B, age and years after thorotrast injection of patients with AGS were statistically higher than those of patients with CLC (age: P less than 0.05; years after thorotrast injection: P less than 0.0001). Hepatocellular carcinoma (HPC) accounted for 17 and 21% of groups A and B, respectively. When yearly distribution, age, and time after thorotrast injection of patients with HPC were correlated with those of patients with other liver cancers, the only statistically significant difference between patients with HPC and patients with CLC (P less than 0.02) was in the years after thorotrast administration. Since 1977 multiple primary liver cancers including AGS developed in thorotrast-administered patients in both groups.